Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2009

01.10.2009 | Original Paper

Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma

verfasst von: Xiaoya Yang, Gang Xiong, Xuedan Chen, Xueqing Xu, Kai Wang, Yong Fu, Kang Yang, Yun Bai

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Survivin is undetectable in normal adult tissues, but has been shown to be overexpressed in various cancers and has been regarded as a marker of malignancy. Polymorphisms which increase the expression of survivin are potential risk factors for esophageal carcinogenesis. The aim of this study is to genotype the survivin promoter polymorphisms namely −31G/C, −241T/C, −625G/C, and −644T/C in esophageal squamous cell cancer patients and controls and to identify a possible association between individual genetic variation and susceptibility to esophageal squamous cell carcinoma (ESCC).

Methods

The expression of survivin in cancer tissues was detected by semiquantitative RT-PCR. A total of 221 Chinese ESCC patients and 268 cancer-free controls were evaluated for the four polymorphisms in survivin promoter. Polymorphisms were identified using the PCR–RFLP technique (−31G/C, −241T/C) or primer-introduced restriction analysis-PCR assay (−644T/C, −625G/C).

Results

Compared with the −625GG genotype, the −625CC genotype was associated with significant elevated risk of ESCC (OR = 2.404, 95% CI = 1.342–4.307). Furthermore, significant difference in survivin expression in esophageal squamous cell cancer tissues was found between subgroups with different −625G/C variants. When we examined the combined effect of the survivin promoter polymorphisms, the haplotypes constructed of −644T/C-−625G/C-−31G/C revealed significant associations with ESCC (global P = 0.0034). −644T-−625C-−31C was a risk haplotype for ESCC (P < 0.001) and −644T-−625G-−31C was a protective haplotype (P = 0.004).

Conclusions

Our finding suggested that survivin promoter polymorphisms −625G/C might influence the susceptibility to ESCC in the Chinese population, maybe by influencing survivin expression.
Literatur
Zurück zum Zitat Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMed Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMed
Zurück zum Zitat Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229. doi:10.1126/science.1069424 CrossRefPubMed Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229. doi:10.​1126/​science.​1069424 CrossRefPubMed
Zurück zum Zitat Ikeguchi M, Yamaguchi K, Kaibara N (2003) Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 24:40–45. doi:10.1159/000070659 CrossRefPubMed Ikeguchi M, Yamaguchi K, Kaibara N (2003) Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 24:40–45. doi:10.​1159/​000070659 CrossRefPubMed
Zurück zum Zitat Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080–1085. doi:10.1053/he.2000.6496 CrossRefPubMed Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080–1085. doi:10.​1053/​he.​2000.​6496 CrossRefPubMed
Zurück zum Zitat Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE, Jung TH, Park JY (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60(1):31–39CrossRefPubMed Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE, Jung TH, Park JY (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60(1):31–39CrossRefPubMed
Zurück zum Zitat Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ (2001) Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 8:305–310. doi:10.1007/s10434-001-0305-0 CrossRefPubMed Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ (2001) Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 8:305–310. doi:10.​1007/​s10434-001-0305-0 CrossRefPubMed
Zurück zum Zitat Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449–462. doi:10.1086/428594 CrossRefPubMed Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449–462. doi:10.​1086/​428594 CrossRefPubMed
Zurück zum Zitat Ugur VI, Kara SP, Kucukplakci B, Demirkasimoglu T, Misirlioglu C, Ozgen A, Elgin Y, Sanri E, Altundag K, Ozdamar N (2008) Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey. Med Oncol 25:63–68. doi:10.1007/s12032-007-0043-7 CrossRefPubMed Ugur VI, Kara SP, Kucukplakci B, Demirkasimoglu T, Misirlioglu C, Ozgen A, Elgin Y, Sanri E, Altundag K, Ozdamar N (2008) Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey. Med Oncol 25:63–68. doi:10.​1007/​s12032-007-0043-7 CrossRefPubMed
Zurück zum Zitat Wagner M, Schmelz K, Dorken B, Tamm I (2008) Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 32(7):1054–1060CrossRefPubMed Wagner M, Schmelz K, Dorken B, Tamm I (2008) Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 32(7):1054–1060CrossRefPubMed
Zurück zum Zitat Xu Y, Fang F, Ludewig G, Jones G, Jones D (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527–537PubMed Xu Y, Fang F, Ludewig G, Jones G, Jones D (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527–537PubMed
Metadaten
Titel
Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma
verfasst von
Xiaoya Yang
Gang Xiong
Xuedan Chen
Xueqing Xu
Kai Wang
Yong Fu
Kang Yang
Yun Bai
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0575-7

Weitere Artikel der Ausgabe 10/2009

Journal of Cancer Research and Clinical Oncology 10/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.